23andMe Initiates Phase 1 Clinical Trial for First Wholly-Owned Immuno-oncology Antibody for Patients with Solid Tumors

NEXT STORY
IBN (InvestorBrandNetwork) Announces Gamechangers LIVE Interview with Mydecine Innovations Group Inc. CEO Joshua Bartch
PREV STORY
The medical audiometer devices market was valued at US$ 129.58 million in 2021
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

European Commission approves Venclyxto plus Gazyvaro for adults with previously untreated chronic lymphocytic leukaemia

author_avatar
NASDAQ Market News

Rafael Pharmaceuticals to Present New Data Validating Efficacy and Tolerability of CPI-613 in Treating Acute Myeloid Leukemia at the 23rd Congress of the European Hematology Association

Newark, NJ, June 14, 2018 (GLOBE NEWSWIRE) -- CPI-613 is Rafael Pharmaceuticals' lead drug ...

author_avatar
NASDAQ Market News

Arcturus Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update

SAN DIEGO, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a ...

author_avatar
NASDAQ Market News